Bristol-Myers Squibb Company (BMY) Balance Sheet

The debt-to-equity ratio moved from roughly 3.2x in mid-2024 to about 1.9x in the latest quarter, but this improvement reflects equity rebuilding rather than debt reduction, since total debt remained above $43B throughout. Retained earnings recovered from $14.9B to $21.2B, which suggests profits are being retained, yet the scale of the liability base implies the balance sheet still depends on sustained earnings to absorb the coming revenue pressure.

The reduction in debt appears to be a deliberate deleveraging path following the Celgene acquisition, and the current debt level remains large relative to the equity base. Refinancing risk is manageable in the near term given cash of $9.6B, but the company's debt service capacity becomes more dependent on the durability of Eliquis and Opdivo cash flows as those assets face erosion.

A current ratio near 1.6 provides adequate coverage of short-term obligations, though it is not a wide margin for a company carrying this level of total debt. The cash position of $9.6B offers a meaningful but not overwhelming buffer against operating shocks, and investors should monitor whether this liquidity is sustained as legacy revenue declines.

Goodwill stability over the period suggests no impairment has yet been recorded, but this concentration creates exposure if acquired franchises underperform against their purchase assumptions. Net PP&E of about $8B is modest relative to the asset base, which indicates an asset-light structure dependent on intangible value that could require write-downs if revenue erosion accelerates.